Contingency Management in the Delivery of HAART to Drug Users in Chennai, India
Primary Purpose
HIV, Substance Abuse, Intravenous
Status
Completed
Phase
Phase 2
Locations
India
Study Type
Interventional
Intervention
Contingency
Prize bowl drawings
Sponsored by
About this trial
This is an interventional treatment trial for HIV focused on measuring Complementary Therapies, Drug Users
Eligibility Criteria
Inclusion Criteria:
- 18 years of age or older
- Provide written informed consent
- Provide a history of injection or non-injection drug use in prior 30 days
- Documented evidence of HIV infection
- Be ART naïve (by self-report)
Satisfy Indian National Guidelines for initiation of HAART (any of the following)
- Absolute CD4+ count < 200 cells/ µl
- AIDS-defining illness with any CD4+ count
- Absolute CD4+ count between 200 - 350 cell/ µl with HIV-related symptoms
Exclusion Criteria:
- Indicates an intention to migrate in the next 12 months
- Any medical or psychiatric condition that the study physician believes to be a contraindication to study participation.
- Enrolled in another HIV treatment program
Sites / Locations
- YR Gaitonde Centre for Substance Abuse-Related Research (YRGCSAR)
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Contingency
Control
Arm Description
Outcomes
Primary Outcome Measures
Time to initiation of HAART
Secondary Outcome Measures
Attendance at HIV treatment visits
HAART possession ratio (a surrogate of medication adherence based on pharmacy fill data)
Proportion with HIV RNA < 400 copies/mL at 6- and 12-months
Changes in absolute CD4 count from baseline at 6- and 12-months
Full Information
NCT ID
NCT01031745
First Posted
December 12, 2009
Last Updated
November 1, 2016
Sponsor
Johns Hopkins University
Collaborators
YR Gaitonde Centre for AIDS Research and Education
1. Study Identification
Unique Protocol Identification Number
NCT01031745
Brief Title
Contingency Management in the Delivery of HAART to Drug Users in Chennai, India
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
May 2011 (undefined)
Primary Completion Date
November 2011 (Actual)
Study Completion Date
November 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Johns Hopkins University
Collaborators
YR Gaitonde Centre for AIDS Research and Education
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Drug use (DU) is a major risk factor for HIV infection in many regions of the world. However, as highly active antiretroviral therapy (HAART) has been rolled out in South and South East Asia, less than 2% of individuals initiated on HAART were drug users (DUs) or former DUs, despite the fact that approximately 20% of HIV infections in the region are ascribed to DU. India is home to about 2.4 million HIV-infected individuals. Though, injection drug users contribute to only about 3% of all HIV infections in India; it is estimated that there are between 168,000 and 1.1 million DUs in India with HIV prevalence about 30%. Novel approaches are needed to engage disenfranchised populations in HIV care in lower and middle income countries, where the burden of HIV disease is growing. Incentive-based strategies (or contingency management) have been shown to be effective in reducing illicit drug use, smoking cessation, and weight loss. Short-term pilot studies have also shown that incentive-based strategies can improve electronically-monitored rates of adherence to HAART in the US, and a recent study in Africa showed that a small incentive approximately doubled the rate that individuals returned to learn the results of their HIV test. However, to date there is no experience with the use of incentive-based interventions to improve engagement into care and risk-reduction among out-of-care HIV-infected DUs in developing world settings. The investigators propose to conduct pilot randomized trial comparing a voucher incentive strategy to a control condition to improve engagement in HIV care and HIV treatment outcomes among out-of-care, treatment-eligible, HIV-infected DUs in Chennai, India. Subjects in the incentive arm will be eligible to earn incentive vouchers for 1) initiating HAART at a government-sanctioned HIV treatment clinic, 2) adherence to scheduled follow-up visits at the HIV clinic, and 3) achieving suppression of HIV RNA. Subjects will be enrolled from a mature research venue in Chennai, YR Gaitonde Centre for Substance Abuse-related Research (YRGCSAR), which focuses the epidemiology and natural history of HIV in DUs. Preliminary data from this pilot study will be used to inform the design of a phase-III study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV, Substance Abuse, Intravenous
Keywords
Complementary Therapies, Drug Users
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Contingency
Arm Type
Experimental
Arm Title
Control
Arm Type
Active Comparator
Intervention Type
Behavioral
Intervention Name(s)
Contingency
Intervention Description
Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
Intervention Type
Other
Intervention Name(s)
Prize bowl drawings
Intervention Description
Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive "bonuses" through prizebowl drawings to offset the inability to earn incentives.
Primary Outcome Measure Information:
Title
Time to initiation of HAART
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Attendance at HIV treatment visits
Time Frame
12-months
Title
HAART possession ratio (a surrogate of medication adherence based on pharmacy fill data)
Time Frame
12-months
Title
Proportion with HIV RNA < 400 copies/mL at 6- and 12-months
Time Frame
12-month
Title
Changes in absolute CD4 count from baseline at 6- and 12-months
Time Frame
12-months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years of age or older
Provide written informed consent
Provide a history of injection or non-injection drug use in prior 30 days
Documented evidence of HIV infection
Be ART naïve (by self-report)
Satisfy Indian National Guidelines for initiation of HAART (any of the following)
Absolute CD4+ count < 200 cells/ µl
AIDS-defining illness with any CD4+ count
Absolute CD4+ count between 200 - 350 cell/ µl with HIV-related symptoms
Exclusion Criteria:
Indicates an intention to migrate in the next 12 months
Any medical or psychiatric condition that the study physician believes to be a contraindication to study participation.
Enrolled in another HIV treatment program
Facility Information:
Facility Name
YR Gaitonde Centre for Substance Abuse-Related Research (YRGCSAR)
City
Chennai
State/Province
Tamil Nadu
ZIP/Postal Code
600113
Country
India
12. IPD Sharing Statement
Citations:
PubMed Identifier
24803381
Citation
Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, Balakrishnan P, Mehta SH, Solomon S, Lucas GM. Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India. Clin Infect Dis. 2014 Aug 15;59(4):589-95. doi: 10.1093/cid/ciu324. Epub 2014 May 6.
Results Reference
result
Learn more about this trial
Contingency Management in the Delivery of HAART to Drug Users in Chennai, India
We'll reach out to this number within 24 hrs